<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37402803</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>31</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1759-4766</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>8</Issue><PubDate><Year>2023</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Nature reviews. Neurology</Title><ISOAbbreviation>Nat Rev Neurol</ISOAbbreviation></Journal><ArticleTitle>Fatty acids might slow ALS progression.</ArticleTitle><Pagination><StartPage>459</StartPage><MedlinePgn>459</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41582-023-00852-9</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kiani</LastName><ForeName>Lisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Nature Reviews Neurology, . nrneuro@nature.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Rev Neurol</MedlineTA><NlmUniqueID>101500072</NlmUniqueID><ISSNLinking>1759-4758</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005227">Fatty Acids</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Neurology. 2023 Jun 21;:null</RefSource><PMID Version="1">37344230</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005227" MajorTopicYN="Y">Fatty Acids</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>31</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>5</Day><Hour>1</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>4</Day><Hour>23</Hour><Minute>21</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37402803</ArticleId><ArticleId IdType="doi">10.1038/s41582-023-00852-9</ArticleId><ArticleId IdType="pii">10.1038/s41582-023-00852-9</ArticleId></ArticleIdList><ReferenceList><ReferenceList><Title>Original article</Title><Reference><Citation>Bjornevik, K. et al. Association of polyunsaturated fatty acids and clinical progression in patients with ALS: post hoc analysis of the EMPOWER Trial. Neurology https://doi.org/10.1212/WNL.0000000000207485 (2023)</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000207485</ArticleId><ArticleId IdType="pubmed">37344230</ArticleId></ArticleIdList></Reference></ReferenceList></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>